Latest Period
n/a
Security Snapshot
Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share (GLTO) Institutional Ownership
CUSIP: 36322Q107
13F Institutional Holders and Ownership History from Q4 2020 to Q3 2024
Institutions Reporting
Shares (Excl. Options)
Price
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Common Stock, par value $0.00001 per share
- Symbol
- GLTO on Nasdaq
- Shares outstanding
- 59,685,400
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- GLTO - Damora Therapeutics, Inc. - Common Stock, par value $0.00001 per share is tracked under CUSIP 36322Q107.
- Latest finished 13F holder period is not available.
- 6 significant owners is listed from Schedule 13D/13G reporting.
Change
- Holder count moved from 20 to 0 between Q2 2024 and Q3 2024.
- SEC-reported value moved from $1,914,098 to $0.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Schedule 13D/G
Open SEC evidence
Ownership context comes from Schedule 13D/G and available holder history for this CUSIP.
Security key
36322Q107
Latest holder period
n/a
13F holders
13D/G owners
6
CIK / CUSIP context first
GLTO full holder history
Damora Therapeutics, Inc. SEC filings
Damora Therapeutics, Inc. company facts
Damora Therapeutics, Inc. insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 36322Q107:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
6
Security
GLTO
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Avoro Capital Advisors LLC | 6.3% | 3,783,000 | Avoro Capital Advisors LLC | 31 Mar 2026 | ||||
| Paragon Therapeutics, Inc. | 3.4% | 2,045,473 | Paragon Therapeutics, Inc. | 09 Feb 2026 | ||||
| Paramora Holding LLC | 3.4% | 2,045,473 | Paramora Holding LLC | 09 Feb 2026 | ||||
| Point72 Asset Management, L.P. | 2% | 1,193,708 | Point72 Asset Management, L.P. | 31 Mar 2026 | ||||
| Otto Erik | 6.3% | -22% | 385,000 | -77% | Otto Erik | 10 Feb 2026 | ||
| Ikarian Capital, LLC | 0.6% | -95% | 335,710 | +18% | Ikarian Capital, LLC | 28 Feb 2026 |
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
16
Latest
n/a
Rows shown
1-16 of 16
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2024 Q3 | 0 | $0 | -$1,904,041 | 0 | |
| 2024 Q2 | 4,036,280 | $1,914,098 | -$7,306 | $0.47 | 20 |
| 2024 Q1 | 3,955,560 | $3,086,219 | +$84,662 | $0.78 | 24 |
| 2023 Q4 | 3,850,203 | $2,771,751 | -$1,147,867 | $0.72 | 19 |
| 2023 Q3 | 5,447,043 | $3,919,925 | -$6,230,492 | $0.72 | 21 |
| 2023 Q2 | 10,195,650 | $25,692,234 | +$3,108,586 | $2.52 | 27 |
| 2023 Q1 | 8,962,608 | $17,835,944 | +$164,580 | $1.99 | 25 |
| 2022 Q4 | 8,879,970 | $10,210,816 | -$425,605 | $1.15 | 22 |
| 2022 Q3 | 9,162,327 | $17,316,000 | +$113,505 | $1.89 | 25 |
| 2022 Q2 | 9,102,298 | $15,746,000 | -$1,143,010 | $1.73 | 21 |
| 2022 Q1 | 9,565,150 | $21,044,000 | -$1,247,710 | $2.20 | 24 |
| 2021 Q4 | 10,056,300 | $30,470,000 | -$1,059,530 | $3.03 | 24 |
| 2021 Q3 | 10,398,274 | $37,206,000 | -$5,044,237 | $3.59 | 25 |
| 2021 Q2 | 11,371,502 | $57,371,000 | -$12,450,152 | $5.06 | 24 |
| 2021 Q1 | 13,693,226 | $82,938,000 | -$3,196,797 | $6.07 | 17 |
| 2020 Q4 | 14,108,246 | $174,674,000 | +$174,674,000 | $12.50 | 19 |